Not Tagged
Not Tagged
['mesothelioma']
phase i data presented by dr. tim yap (ct006) represent the first clinical proof-of-concept for targeting the hippo-yap-tead pathway in patients with advanced malignant mesothelioma and other tumors with nf2 mutations: #aacr23 3/3
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789